TET1 CRISPR/Cas9 KO Plasmid (h): sc-400845
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TET1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TET1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TET1 Antibody (4F4): sc-293186
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TET1 CRISPR/Cas9 KO Plasmid (h) | sc-400845 | 20 µg | $397.00 |
Overview
TET1 (ten-eleven translocation methylcytosine dioxygenase 1) is an Fe(II)/2-oxoglutarate–dependent dioxygenase that catalyzes oxidation of 5-methylcytosine to 5-hydroxymethylcytosine and further oxidized derivatives, supporting active DNA demethylation and epigenetic remodeling. Through interactions with transcriptional regulators and chromatin-associated complexes, TET1 helps shape promoter and enhancer methylation states that influence cell identity, differentiation, and genome stability. TET1-linked changes in 5hmC landscapes have been associated with dysregulated gene expression programs in cancer and neurodevelopmental contexts, and are frequently studied alongside other DNA methylation machinery such as DNMTs and IDH-dependent metabolic pathways. As an epigenetic writer/eraser interface, TET1 is widely used to interrogate methylation-dependent control of signaling networks and lineage-specific transcription.
TET1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TET1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TET1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TET1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TET1 protein expression.
This CRISPR knockout system enables efficient generation of TET1-deficient cell models for investigation of TET1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TET1 exon(s) critical for TET1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TET1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TET1 CRISPR/Cas9 KO Plasmid (h) and TET1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TET1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TET1 HDR Plasmid (h) and TET1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TET1 homology arms to support homology-directed repair at defined TET1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.